A immunostaining with anti-herceptin-2 [Her-2] can be used because it is sometimes positive in skin metastases a mammary adenocarcinoma, whereas carcinomas primary cutaneous apocrine or eccrine do not set the anti-Her-2 [12]. Here, ERBB2 is linked to breast adenocarcinoma.